WASHINGTON, July 13, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven value-based specialty care solutions to payers and providers, announced today that it will release its second quarter 2023 financial results on Wednesday, August 2, 2023, after market close, with a conference call to follow at 5 p.m. ET.
Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 855.940.9467 or 412.317.6034 for international callers and referencing the "Evolent call" 15 minutes prior to the call. An audio playback of the conference call will be available on Evolent's investor relations website, ir.evolenthealth.com, for 90 days after the call.
About Evolent
Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolent.com.
Contact:
Seth R. Frank
Vice President, Investor Relations
Evolent
This email address is being protected from spambots. You need JavaScript enabled to view it.
571-895-3919 (W)
Last Trade: | US$9.23 |
Daily Change: | -0.06 -0.65 |
Daily Volume: | 2,082,375 |
Market Cap: | US$1.060B |
February 20, 2025 February 04, 2025 November 07, 2024 November 07, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load